CLINICAL RESPONSE OF ACCELERATED HYPOFRACTIONATED RADIOTHERAPY IN INOPERABLE NON-SMALL CELL LUNG CANCER PATIENTS

Phase 3

Completed

• Conditions: on- small cell lung cancer; Non- Accelerated hypofractionated radiotherapy; Response; Toxicity

• Registration Number: TCTR20200110001
• Lead Sponsor: Self

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2018-12-31
• Study Start: 2020-01-10
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

Inclusion criteria
1. Unresectable or medically inoperable non-small cell lung cancer patients
2. Patients who are unfit for chemotherapy due to some comorbidities (E.g., poor cardiac, liver or renal function, etc., or old age)
3. Patients with ECOG performance status 0,1 or 2

Exclusion Criteria

Exclusion criteria
1. Patients with distant metastasis
2. Patients previously treated with thoracic radiotherapy or chemotherapy
3. Patients with small cell lung cancer

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical response 6 weeks after radiotherapy RECIST guideline version 1.1 (CT scan chest)

Secondary Outcome Measures

Name	Time	Method
Acute toxicities pretreatment (baseline), weekly during radiotherapy, 6 weeks and 12 weeks after radiotherapy CTCAE version 5 (symptons assessment)